Lewis County Health System debuts new 3D mammography technology
In a recent announcement, LCHS has announced the installation of the Hologic 3D Dimensions mammography system with Genius AI. This brings state-of-the-art breast cancer screening technology to the Lewis County community. The 'cutting-edge system enhances early detection, improves diagnostic accuracy, and provides a more comfortable experience for patients.'
Some breast cancer patients can avoid certain surgeries, studies suggest
Over the last eight years, the health system has consistently invested in new equipment and technology. With this latest investment, women have access to the highest level of breast health technology in the region and don't have to travel out of the area to access needed care.
Gerald R. Cayer, LCHS Chief Executive
The Hologic 3D Dimensions system with Genius AI represents the latest advancement in breast imaging, offering:
Superior 3D Mammography – Detects breast cancer earlier with clearer, more detailed images.
Genius AI™ Technology – Uses artificial intelligence to assist radiologists in identifying potential abnormalities faster and with greater precision.
Reduced Need for Additional Imaging – Lowers recall rates, meaning fewer patients need to return for unnecessary follow-up exams.
Enhanced Comfort – Designed with SmartCurve technology, providing a more comfortable mammogram experience without compromising image quality.
According to LCHS, breast cancer remains the most common cancer among women, and early detection is critical for successful treatment. With this new technology, LCHS continues its commitment to delivering the most advanced, accurate, and patient-friendly breast imaging services in the region.
For more information about breast health services, call 315-376-5213 or visit www.lcgh.net.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
American Press
2 days ago
- American Press
Dr. Richard Edward Landry
Dr. Richard Edward Landry passed away Thursday, Aug. 14, 2025, after a brief illness, leaving behind a legacy as rich and enduring as the Louisiana soil that shaped him. Born on Oct. 4, 1943, in Lake Charles to Lee and Willie Landry, 'Dick' was the second of four children and the family's only son—a distinction that prepared him well for a lifetime of being lovingly outnumbered by the remarkable women in his life. Dick's roots ran deep in Southwest Louisiana, attending local schools including Lake Charles High School, where as a member of the 1958 State Championship football team, he learned early that success comes through teamwork, dedication, and perhaps a little healthy competition. But it was in typing class—of all places—where he would make his most important discovery: Gaye Revelle, the love of his life and future partner in all his many adventures. One can only imagine the young man's relief that his hunt-and-peck typing skills didn't scare away the girl who would become his devoted wife of 57 years. Following his graduation from LCHS in 1961, Dick enrolled at McNeese State University, where his track career and his studies would be interrupted by a call to serve his country—a call he answered without hesitation. Dick served with distinction in the U.S. Army in Vietnam as a medic in the infantry. His service exemplified the courage and compassion that would define his entire life—running toward danger to heal others, armed with both medical knowledge and an unshakeable faith. When his service concluded, Dick returned to Louisiana with three clear missions: marry his sweetheart, complete his education, and begin the next chapter of a life devoted to healing. In 1968, he and Gaye wed, beginning a marriage that would become a testament to enduring love, mutual respect, and shared purpose. Dick completed his undergraduate degree at McNeese before heading to New Orleans to attend LSU School of Medicine. Balancing medical school with newlywed life and the arrival of their growing family required the kind of stamina that would have impressed his old track coaches. After earning his Medical Degree, Dick returned home to complete his Family Practice Residency at Moss Regional Hospital, where Lake Charles—and the broader community—gained not just another physician, but 'Doc'—a healer whose prescription often included equal parts medical wisdom and genuine human connection. For over three decades, Doc served the Lake Charles community as a Family Physician, treating everything from childhood scraped knees to complex medical conditions. His patients quickly discovered that appointments with Doc often ran long—because he genuinely cared about their lives beyond their symptoms. He remembered birthdays, asked about grandchildren, and somehow always found time to listen, really listen, to what people needed to share. His colleagues at local hospitals came to recognize Doc's distinctive approach: thorough, compassionate, and infused with a faith that never felt imposed but always offered comfort. He had the rare gift of making complex medical conditions understandable without talking down to patients, and his gentle humor could ease anxiety in even the most stressful situations. Above all else, Doc was a devoted follower of Jesus Christ, and his faith wasn't something he only wore on Sundays—it was woven into every aspect of his daily life. As a longtime and active member of Trinity Baptist Church, he served as Deacon, Sunday School Teacher, and Trustee, but these titles barely captured his true role as a spiritual mentor and friend to countless individuals. Doc's vision extended far beyond Lake Charles. His service on the International Mission Board for the Southern Baptist Convention coincided with countless medical mission trips across Africa, Asia, Central America, and beyond. These weren't mere charitable ventures—they were expressions of Doc's conviction that healing bodies and nurturing souls were inseparable callings. Those who joined him on mission trips often marveled at his boundless energy and enthusiasm. Whether treating patients in remote clinics or sharing his faith around evening campfires, Doc approached each day as a new opportunity to serve. His passport told the story of a man who saw no borders when it came to compassion, no boundaries when it came to love. Doc's zest for life extended well beyond his medical practice. A passionate supporter of Barbe High School athletics, he served as the Football Team Doctor for several years, combining his love of sports with his dedication to young people's wellbeing. Friday night lights held special meaning for Doc—not just as entertainment, but as opportunities to be present for the community's next generation. His friends and family often joked that Doc never met a stranger, only friends he hadn't properly introduced himself to yet. His enthusiasm was infectious, whether he was discussing the latest advances in family medicine, sharing stories from his mission trips, or simply celebrating the everyday joys of life in Louisiana. While Doc touched countless lives in his professional and volunteer work, his greatest pride and joy centered on his family. He and Gaye created a home filled with love, laughter, and the beautiful chaos that comes with raising four daughters. Doc often said that being outnumbered 5-to-1 taught him patience, diplomacy, and the fine art of strategic communication—skills that served him well in both family life and medical practice. His daughters—Laurel, Wendy, Leslie, and Kelly—knew their father as a man who could be both gentle healer and enthusiastic cheerleader, wise counselor and silly companion. He taught them by example that strength comes in many forms, that faith can move mountains, and that the best way to honor God is to serve others with joy. The arrival of nine grandchildren brought new dimensions to Doc's happiness. 'Da' approached grandparenthood with the same enthusiasm he brought to everything else, creating special traditions, sharing his love of adventure, and ensuring that each grandchild knew they were uniquely precious and deeply loved. Dr. Richard Edward Landry lived his 81 years with purpose, passion, faith, and an unwavering commitment to making the world a little brighter for everyone he encountered. He was a healer who understood that medicine is as much about hope as it is about science, a man of faith who lived his beliefs through action rather than words alone, and a devoted family man who created a legacy of love that will continue through generations. His life reminds us that true success isn't measured in achievements alone, but in the lives we touch, the love we share, and the example we set. Doc did all of this with a smile that could light up a room, a laugh that was genuinely contagious, and a heart that seemed to have infinite capacity for caring. Dr. Landry is survived by his devoted wife of 57 years, Gaye Revelle Landry. He is also survived by his three sisters: Sandy Moore and her husband Nolan, Marsha Chapman and her husband Ted, and Willie Mount; his four daughters: Laurel Carleton and her husband Mark, Wendy Lechtenberg and her husband Keith, Leslie Bradley and her husband Rex, and Kelly Ortiz and her husband Emilio; and his nine grandchildren: Camille and Richard Carleton, Madeline Stewart and her husband Vance, Abbie and Callie Lechtenberg; Bella, Julia, Anna, and Clara Bradley. He was preceded in death by his parents, Lee and Willie Landry; his father-in-law, Elmer Revelle; his mother-in-law, Mable Revelle; and his brother-in-law, Ben Mount. A celebration of Dr. Landry's life will be held at Trinity Baptist Church on Saturday, August 16, 2025. Visitation will be from 9 a.m. to 12 p.m., followed by the funeral service at 2 p.m. The service will be officiated by Dr. David Rose, Rev. Steve James, and Dr. David Hankins—a fitting tribute to a man whose life was enriched by deep spiritual friendships. Burial will follow at Highland Memory Gardens under the direction of Johnson Funeral Home. In lieu of flowers, and in keeping with Doc's lifelong commitment to healing and service, memorial donations may be made to Trinity Baptist Church's 'Medical Mission Fund'—ensuring that his legacy of bringing hope and healing to those in need will continue long into the future. 'Well done, good and faithful servant.' – Matthew 25:23
Business Wire
3 days ago
- Business Wire
Grove Biopharma to Participate in Materials Biology Symposium at ACS Fall 2025 Scientific Meeting
CHICAGO--(BUSINESS WIRE)--Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, announced today it will present an update at the annual American Chemical Society (ACS) Fall meeting being held August 17-21, 2025, in Washington D.C. This symposium spotlights how advances in modern polymer chemistry and materials science are informing our understanding of biology Share The symposium, taking place on Monday, August 18 and titled Materials Biology: Precision Macromolecules for Probing and Perturbing Cellular Processes, will include presentations about peptide, protein and glycomimetic materials and the critical role they play in understanding and impacting human disease. These insights have the potential to unlock new therapeutic strategies in the development of next-generation medicines. 'This symposium spotlights how advances in modern polymer chemistry and materials science are informing our understanding of biology,' said Nathan Gianneschi, Ph.D., Scientific Founder of Grove Biopharma and Professor at Northwestern University. 'By designing synthetic polymers that can precisely interact with cells and proteins at the same scale as natural biomolecules, we are opening new pathways to study and influence complex cellular processes. This emerging field, what we call 'materials biology', is focused on the role of synthetic precision macromolecules and nanomaterials in understanding the natural world.' 'At Grove, we are pioneering Bionic Biologics—a new class of therapeutics that integrates biologic and synthetic design, accelerated by computation, to develop molecules capable of selectively inhibiting or degrading even the most challenging intracellular targets,' said Paul Bertin, Ph.D., Co-Founder, President and Chief Technology Officer at Grove Biopharma. 'By integrating protein and peptide engineering, precision polymer chemistry and medicinal chemistry, we can create fully synthetic, cell penetrant, protein-scale molecules to address complex protein-scale problems. We see the potential for Bionic Biologics in oncology and neurodegenerative diseases, offering a novel alternative to existing approaches.' About Grove Biopharma Grove Biopharma is a private biotechnology company pioneering its proprietary Bionic Biologics™ platform to develop novel therapies targeting intracellular protein-protein interactions. Bionic Biologics represent a novel therapeutic modality that integrates principles of biologic and synthetic design. This innovative platform enables the targeting of well-validated yet previously intractable disease drivers, unlocking new possibilities for therapeutic intervention. A spinout from Northwestern University, Grove brings together a multidisciplinary team of chemists, biologists, materials scientists and entrepreneurs. The company is based in Chicago, embedded within the city's emerging life sciences ecosystem. For more information, please visit
Business Wire
3 days ago
- Business Wire
Tivic Reports Second Quarter 2025 Financial Results
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. 'We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems,' stated Tivic CEO Jennifer Ernst. 'To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit the ClearUP business by the end of this year,' continued Ernst. 'I look forward to advancing the commercialization of these life-saving therapies, supporting our strategy to increase shareholder value through this transformation.' Corporate Highlights from the Second Quarter and Subsequent Weeks, included: Securing positive interest in potential military and defense applications for drug candidate Entolimod™ to treat ARS during briefings with the White House and U.S. Food & Drug Administration (FDA) officials. Extending the worldwide license of Entolimod™ to include the treatment of neutropenia, a condition that reduces the body's ability to combat infections and has a wide range of causes - from genetics to cancer treatments and age. Entering into a GMP manufacturing validation agreement with Scorpius Biomanufacturing, Inc. as part of preparing for the FDA biologics license application process. Completing all study visits in the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Raising $1.4 million from the first and second tranche of a preferred equity purchase agreement that provides for up to $8.4 million in total financing. Entering into a $25 million equity line of credit that generated net proceeds of $547,000. Receiving shareholder approval of key measures in support of Tivic transformation strategy. Expanding biopharmaceutical team with regulatory, clinical and business development staff. Naming Lisa Wolf as CFO following her nine-month tenure as interim CFO. Financial Performance: Revenue (net of returns) for the three and six months ended June 30, 2025 totaled $86,000 and $156,000, respectively, compared with $140,000 and $474,000 for 2024. The decreases are due to lower unit sales of ClearUP™ to treat sinus pain and pressure. The lower sales are attributable to decreases in advertising expenses as the company focused resources on accelerating its TLR5 program for the development of Entolimod™ for ARS. Gross profit in the three and six months ended June 30, 2025 was $54,000 and $104,000, respectively, compared to $30,000 and $197,000 in 2024. Gross margin was 67% in the six months ended June 30, 2025, compared to 42% in 2024. Operating expenses in the three and six months ended June 30, 2025 was $2.0 million and $3.5 million, respectively, compared to $1.3 million and $3.0 million in 2024. The increases were primarily due to the addition of the biopharma programs in February 2025. Net loss of $1.9 million for the three months ended June 30, 2025, compared to $1.3 million in the second quarter of 2024. Net loss of $3.4 million for the first half of 2025, compared to $2.7 million for the first half of 2024. At June 30, 2025, cash and cash equivalents totaled $1.2 million, compared with $2.0 million, at December 31, 2024. Subsequent to quarter's end, the Company raised a total of $0.9 million through utilization of its equity line of credit and the sale of Series B Preferred Stock pursuant to its preferred equity purchase agreement. The company has no debt on its balance sheet. Approximately $7.0 million remains available as a committed investment in Tivic through a preferred equity purchase agreement. The company believes the current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod. Conference Call and Webcast Information Management will host a webcast/conference call today, Thursday, August 14, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the company's second quarter 2025 financial results and provide a business update. Webcast Link An audio replay of the call will be available for the next 90 days from the investor page on the Tivic Health website at About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. Tivic Health Systems, Inc. Condensed Statements of Operations (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUES $ 86 $ 140 $ 156 $ 474 COST OF SALES 32 110 52 277 GROSS PROFIT 54 30 104 197 OPERATING EXPENSES Research and development 655 302 990 558 Sales and marketing 426 207 605 712 General and administrative 907 787 1,949 1,674 TOTAL OPERATING EXPENSES 1,988 1,296 3,544 2,944 NET OPERATING LOSS (1,934 ) (1,266 ) (3,440 ) (2,747 ) OTHER INCOME, NET 3 0 7 0 NET LOSS $ (1,931 ) $ (1,266 ) $ (3,433 ) $ (2,747 ) NET LOSS PER SHARE - BASIC AND DILUTED $ (2.19 ) $ (5.37 ) $ (4.64 ) $ (17.05 ) WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED 881,294 235,868 739,618 161,103 Expand
